Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Capital Expenditures: 2019-2024

Historic Capital Expenditures for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $5.5 million.

  • GeneDx Holdings' Capital Expenditures rose 655.45% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 251.82%. This contributed to the annual value of $5.5 million for FY2024, which is 4.59% up from last year.
  • Per GeneDx Holdings' latest filing, its Capital Expenditures stood at $5.5 million for FY2024, which was up 4.59% from $5.2 million recorded in FY2023.
  • GeneDx Holdings' Capital Expenditures' 5-year high stood at $24.1 million during FY2020, with a 5-year trough of $5.2 million in FY2023.
  • Over the past 3 years, GeneDx Holdings' median Capital Expenditures value was $5.5 million (recorded in 2024), while the average stood at $6.0 million.
  • In the last 5 years, GeneDx Holdings' Capital Expenditures surged by 102.08% in 2020 and then crashed by 52.74% in 2021.
  • Yearly analysis of 5 years shows GeneDx Holdings' Capital Expenditures stood at $24.1 million in 2020, then crashed by 52.74% to $11.4 million in 2021, then slumped by 37.06% to $7.2 million in 2022, then decreased by 26.74% to $5.2 million in 2023, then increased by 4.59% to $5.5 million in 2024.